MedTrace Logo

Comparison of Standard vs. Accelerated Corneal Crosslinking

NCT03922542 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 510

Last updated 2025-07-31

No results posted yet for this study

Summary

The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.

Conditions

  • Keratoconus
  • Ectasia Corneal

Interventions

COMBINATION_PRODUCT

riboflavin 0.1%

Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes

COMBINATION_PRODUCT

Riboflavin 0.1%

Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes

Sponsors & Collaborators

  • Price Vision Group

    lead INDUSTRY

Principal Investigators

  • Francis W Price, Jr., MD · Price Vision Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-16
Primary Completion
2026-06-01
Completion
2026-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03922542 on ClinicalTrials.gov